Log in to save to my catalogue

Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ...

Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04831050v1

Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial

About this item

Full title

Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2024-06, Vol.25 (6), p.720-730

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundThe KEYNOTE-057 trial evaluated activity and safety of pembrolizumab in patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer who were ineligible for or declined radical cystectomy. In cohort A (patients with carcinoma in situ, with or without papillary tumours) of the KEYNOTE-057 study, pembrolizumab monother...

Alternative Titles

Full title

Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_04831050v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04831050v1

Other Identifiers

ISSN

1470-2045,1474-5488

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(24)00178-5

How to access this item